Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Advera Health Release Analysis of Post-Marketing Adverse Drug Reactions for Type 2 Diabetes DrugsFeatured Side Effects for GLP-1 (AstraZeneca), DPP-4 (Takeda), and SGLT2 (AstraZeneca)
By: Advera Health Analytics, Inc. Type 2 diabetes increases risk for serious coronary, kidney, nerve, and other complications in over 200 million people. Adverse events (AEs) associated with drugs intended to treat diabetes are important to quantify and understand because strict medication adherence is needed to reduce the complications listed above. The results of Advera Health’s analysis showed interesting safety and cost differences both within- and across diabetes medication classes: Elevated reporting rates for pancreatitis, hypoglycemia, and diabetic ketoacidosis add to suspicions of class-wide side effect issues, especially for DPP-4 drugs While all drug classes had members with elevated reporting for diabetic ketoacidosis, the SGLT2 inhibitors had much higher RORs than the other two classes with a 38.36 for canagliflozin and a 34.15 for dapagliflozin. The top 3 highest downstream costs did not show any class-specificity as they were associated with exenatide (Byetta - AstraZeneca) Methodology: Substantial costs are associated with AEs and they represent a significant burden on the healthcare system. Improved analysis of post-marketing AEs combined with the quantification of downstream AE and outcome costs provide an improved method for assessing real-world safety and financial impact. ABOUT ADVERA HEALTH ANALYTICS Advera Health Analytics is a health informatics company that improves patient safety and reduces systemic healthcare costs through the comprehensive analysis of real world outcomes data. Advera Health Analytics makes these data accessible, actionable, and predictable. For more information visit adverahealth.comand connect with us on LinkedIn, Twitter (https://twitter.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|